Takahashi, Hiroto
Xia, Peng
Cui, Jiankun
Talantova, Maria
Bodhinathan, Karthik
Li, Wenjun
Saleem, Sofiyan
Holland, Emily A.
Tong, Gary
Piña-Crespo, Juan
Zhang, Dongxian
Nakanishi, Nobuki
Larrick, James W.
McKercher, Scott R.
Nakamura, Tomohiro
Wang, Yuqiang
Lipton, Stuart A.
Article History
Received: 11 March 2015
Accepted: 9 September 2015
First Online: 19 October 2015
Change Date: 12 February 2016
Change Type: Update
Change Details: A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has been fixed in the paper.
Competing interests
: The authors declare that S.A.L. is the inventor on world-wide patents for the use of memantine and NitroMemantine for neurodegenerative disorders; Y.W. and J.W.L. are also named inventors on patents for NitroMemantine. Per Harvard University guidelines, S.A.L. participates in a royalty-sharing agreement with his former institution Boston Children’s Hospital/Harvard Medical School, which licensed the drug memantine (Namenda®) to Forest Laboratories/Actavis. Additionally, S.A.L. and J.W.L. are scientific founders of Adamas Pharmaceuticals, Inc., which has developed second-generation formulations of memantine with Forest/Actavis.